Transthyretin (TTR) Y78F Variant Filaments

Human Recombinant Transthyretin (TTR) Y78F Variant Filaments

Product Specifications

Background

Transthyretin is a transport protein in the serum and cerebospinal fluid that carried the thyroid hormone Thyroxine and retinol-binding protein bound to retinol. TTR misfolding and aggregation is known to be associated with the amyloiddiseases SSA, FAP and FAC (1-5) . TTR is also thought to have beneficial side effects, such as binding to beta-amyloid protein, preventing beta-amyloid from accumulating into the plaques associated with Alzheimer's Disease (6) . The mutant variant Y78F indicates a destabilization of the contacts between the alpha-helix and AB loop and the body of the molecule, potentially leading to applications in immne therapy for FAP (7) .

Product Name Alternative

Amyloid polyneuropathy Protein, Amyloidosis I Protein, ATTR Protein, Carpal tunnel syndrome 1 Protein, CTS Protein, CTS1 Protein, HEL111 Protein, HsT2651 Protein, PALB Protein, Prealbumin Protein, Prealbumin amyloidosis type I Protein, Prealbumin Thyroxine-binding Protein, TBPA Protein, Thyroxine binding prealbumin Protein, Transthyretin Protein, TTHY_HUMAN Protein, TTR Protein

UNSPSC

12352202

UN Code

Non-hazardous

Hazard Statement

Non-hazardous

Gene ID

7276

Swiss Prot

P02766

Accession Number

NP_000362.1

Cellular Locus

Cytoplasm | Extracellular exosome | Extracellular Region | Lysosome

Expression System

E. coli

Host

E. coli

Origin Species

Human

Target

Transthyretin (TTR)

Conjugation

No Tag

Nature

Recombinant

Applications

WB | SDS-PAGE | In vivo assay | In vitro assay

Field of Research

Purification Method

Ion-exchange Purified

Purification

Ion-exchange Purified

Limit Of Detection

Certified >95% pure using SDS-PAGE analysis. Low endotoxin <5 EU/mL @ 2mg/mL.

Concentration

Lot/batch specific. See included datasheet.

Purity

>95%

Weight

0.5

Length

Full length

Buffer

PBS pH 7.4

Molecular Weight

13.876 kDa

Precautions

Not for use in humans. Not for use in diagnostics or therapeutics. For research use only.

Additionnal Information

For best results, sonicate immediately prior to use. Refer to the Neurodegenerative Protein Handling Instructions on our website, or the product datasheet for further information. Monomer source is catalog# SPR-452.

References & Citations

1. Zeldenrust S.R., Benson M.D. (2010). Wiley. pp. 795–815. 2. Westermark P., Sletten K., Johansson B., Cornwell G.G. (1990). Proc. Natl. Acad. Sci. U.S.A. 87(7): 2843–5. 3. Andrade C. (1952). Brain. 75(3): 408–27. 4. Coelho T. (1996). Curr. Opin. Neurol. 9(5): 355–9. 5. Jacobson D.R, et. al. (1997). N. Engl. J. Med. 336(7): 466–73. 6. Li X. (2011). Mol Neurodegener. 6(1):79. 7. Terazaki H.,m et al. (2006) Lab Invest. 86(1): 23-31.

Shipping Conditions

Dry Ice. Shipping note: Product will be shipped separately from other products purchased in the same order.

Storage Conditions

-80ºC

Notes

Protein Length

Full length

Background Reference 01

1. Zeldenrust S.R., Benson M.D. (2010) . Wiley. pp. 795–815. 2. Westermark P., Sletten K., Johansson B., Cornwell G.G. (1990) . Proc. Natl. Acad. Sci. U.S.A. 87 (7) : 2843–5. 3. Andrade C. (1952) . Brain. 75 (3) : 408–27. 4. Coelho T. (1996) . Curr. Opin. Neurol. 9 (5) : 355–9. 5. Jacobson D.R, et. al. (1997) . N. Engl. J. Med. 336 (7) : 466–73. 6. Li X. (2011) . Mol Neurodegener. 6 (1) :79. 7. Terazaki H., m et al. (2006) Lab Invest. 86 (1) : 23-31.